Connor, Clark & Lunn Investment Management (CC&L)’s Arcturus Therapeutics ARCT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-74,830
| Closed | -$1.82M | – | 1424 |
|
|
2024
Q2 | $1.82M | Sell |
74,830
-41,115
| -35% | -$1M | 0.01% | 676 |
|
|
2024
Q1 | $3.92M | Buy |
115,945
+16,203
| +16% | +$547K | 0.02% | 490 |
|
|
2023
Q4 | $3.14M | Buy |
99,742
+64,520
| +183% | +$2.03M | 0.01% | 552 |
|
|
2023
Q3 | $900K | Sell |
35,222
-8,412
| -19% | -$215K | ﹤0.01% | 852 |
|
|
2023
Q2 | $1.25M | Buy |
+43,634
| New | +$1.25M | 0.01% | 734 |
|
|
2022
Q3 | – | Sell |
-19,276
| Closed | -$303K | – | 1105 |
|
|
2022
Q2 | $303K | Sell |
19,276
-35,324
| -65% | -$555K | ﹤0.01% | 861 |
|
|
2022
Q1 | $1.47M | Sell |
54,600
-33,299
| -38% | -$898K | 0.01% | 580 |
|
|
2021
Q4 | $3.25M | Buy |
87,899
+9,817
| +13% | +$363K | 0.02% | 421 |
|
|
2021
Q3 | $3.73M | Buy |
+78,082
| New | +$3.73M | 0.02% | 403 |
|